Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Tharimmune Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
THAR
Nasdaq
8731
https://tharimmune.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Tharimmune Inc
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
- May 2nd, 2024 5:34 pm
Tharimmune To Participate in Two Upcoming Investor Conferences in May
- Apr 30th, 2024 12:31 pm
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
- Apr 29th, 2024 1:00 pm
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
- Apr 23rd, 2024 11:31 am
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
- Apr 15th, 2024 12:31 pm
Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now
- Mar 6th, 2024 12:00 pm
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
- Mar 5th, 2024 1:31 pm
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
- Feb 20th, 2024 1:01 pm
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
- Feb 5th, 2024 1:30 pm
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
- Jan 29th, 2024 1:00 pm
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
- Dec 11th, 2023 1:01 pm
Tharimmune, Inc. Announces Closing of $11 Million Public Offering
- Nov 30th, 2023 9:01 pm
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
- Nov 30th, 2023 2:45 pm
Tharimmune, Inc. Announces Pricing of $10 Million Public Offering
- Nov 28th, 2023 2:40 am
Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)
- Nov 27th, 2023 1:00 pm
Tharimmune Announces 1-for-25 Reverse Stock Split
- Nov 17th, 2023 12:00 pm
Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis
- Nov 6th, 2023 10:35 pm
Scroll